Curis Lifesciences Ltd

Curis Lifesciences Ltd

₹ 133 -1.52%
25 Nov - close price
About

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]

Key Points

Business Profile[1]
Curis Lifesciences is a pharmaceutical company engaged in the production of a wide range of formulations across tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.

  • Market Cap 107 Cr.
  • Current Price 133
  • High / Low 148 / 128
  • Stock P/E 20.0
  • Book Value
  • Dividend Yield 0.00 %
  • ROCE %
  • ROE %
  • Face Value 10.0

Pros

Cons

  • Promoter holding has decreased over last quarter: -24.6%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2024
9.12
6.39
Operating Profit 2.73
OPM % 29.93%
0.00
Interest 0.25
Depreciation 0.17
Profit before tax 2.31
Tax % 48.05%
1.20
EPS in Rs 24.00
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
35.42 35.58
32.16 27.14
Operating Profit 3.26 8.44
OPM % 9.20% 23.72%
0.34 0.31
Interest 1.33 0.85
Depreciation 0.73 0.68
Profit before tax 1.54 7.22
Tax % 20.13% 25.90%
1.23 5.36
EPS in Rs 24.60 107.20
Dividend Payout % 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 0%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 336%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
Equity Capital
Reserves
Total Liabilities
CWIP
Investments
Total Assets

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
Net Cash Flow

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %

Shareholding Pattern

Numbers in percentages

4 Recently
Nov 2025
68.03%
2.93%
10.86%
18.17%
No. of Shareholders 542

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents